Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC. Read More ›
Triplet combination of the anti-CD47 antibody magrolimab + azacitidine and venetoclax was safe and yielded high CR/CRi rates in newly diagnosed AML patients. Read More ›
Addition of the anti-CD70 antibody cusatuzumab to current standard-of-care venetoclax/azacitidine was generally well-tolerated and showed promising antileukemic activity in elderly patients with untreated AML. Read More ›
Triplet combination of IMGN632 (an αCD123 ADC) plus azacitidine and venetoclax was associated with a manageable safety profile and promising antileukemic activity in relapsed/refractory AML patients. Read More ›
Low-intensity regimen of venetoclax plus cladribine/low-dose AraC alternating with azacitidine was well-tolerated and produced high response rates with durable MRD-negative remissions among older/unfit patients with newly diagnosed AML. Read More ›
CD7-targeted CAR-T therapy was associated with a manageable safety profile and produced complete remission in patients with CD7-positive mixed phenotype acute leukemia. Read More ›
Myelofibrosis patients typically prepare for allo-SCT by suspending ruxolitinib therapy, which subsequently results in worsening disease manifestations. Continuation of ruxolitinib therapy in an off-label approach offers a safer option according to interim phase 2 data. Read More ›
Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset. Read More ›
Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept. Read More ›
Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells. Read More ›